Acurx Pharmaceuticals (ACXP) Total Non-Current Liabilities (2021 - 2022)
Acurx Pharmaceuticals' (ACXP) quarterly Total Non-Current Liabilities came in at -$144121.0 in Q2 2022, down 1059.02% on a QoQ basis from $15028.0 in Q1 2022.
Acurx Pharmaceuticals (ACXP) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 2 years of Total Non-Current Liabilities data on file, last reported at -$144121.0 in Q2 2022.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to -$144121.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$144121.0 (changed N/A YoY) and the FY2021 annual result came in at $225909.0, changed N/A from the prior year.
- Total Non-Current Liabilities fell to -$144121.0 in Q2 2022, from $15028.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $225909.0 in Q4 2021 to a low of -$144121.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -144,121.00 |
| Mar 31, 2022 | 15,028.00 |
| Dec 31, 2021 | 225,909.00 |